379 related articles for article (PubMed ID: 19664991)
1. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
[TBL] [Abstract][Full Text] [Related]
2. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
3. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
[TBL] [Abstract][Full Text] [Related]
4. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
5. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
6. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
8. Delta-like 4/Notch signaling promotes Apc
Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
[TBL] [Abstract][Full Text] [Related]
9. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
10. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
11. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
12. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
Minuzzo S; Agnusdei V; Pusceddu I; Pinazza M; Moserle L; Masiero M; Rossi E; Crescenzi M; Hoey T; Ponzoni M; Amadori A; Indraccolo S
Carcinogenesis; 2015 Jan; 36(1):115-21. PubMed ID: 25355291
[TBL] [Abstract][Full Text] [Related]
13. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.
Jia X; Wang W; Xu Z; Wang S; Wang T; Wang M; Wu M
Sci Rep; 2016 Jun; 6():27985. PubMed ID: 27301650
[TBL] [Abstract][Full Text] [Related]
14. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
Ridgway J; Zhang G; Wu Y; Stawicki S; Liang WC; Chanthery Y; Kowalski J; Watts RJ; Callahan C; Kasman I; Singh M; Chien M; Tan C; Hongo JA; de Sauvage F; Plowman G; Yan M
Nature; 2006 Dec; 444(7122):1083-7. PubMed ID: 17183323
[TBL] [Abstract][Full Text] [Related]
16. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
[TBL] [Abstract][Full Text] [Related]
17. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer.
Oishi H; Sunamura M; Egawa S; Motoi F; Unno M; Furukawa T; Habib NA; Yagita H
Pancreas; 2010 Aug; 39(6):897-903. PubMed ID: 20182391
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
19. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
20. Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.
Adam MG; Berger C; Feldner A; Yang WJ; Wüstehube-Lausch J; Herberich SE; Pinder M; Gesierich S; Hammes HP; Augustin HG; Fischer A
Circ Res; 2013 Nov; 113(11):1206-18. PubMed ID: 24025447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]